A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs

Joseph Dougherty (Inventor), Annmarie Pacchia (Inventor), Stuart Peltz (Inventor), Yacov Ron (Inventor), Sofiya Micheva-Viteva (Inventor)

Research output: Innovation

Abstract


Invention Summary:

Background: Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication of virus in patients. The half-life of the latently infected population is quite long. To fully eliminate virus, small molecules that can reach and activate latent viral reservoirs could potentially be utilized to eliminate the latent arm of the infection by the combination with current antiretroviral therapy.

Invention: This technology is a cell-based assay for high-throughput screening for novel compounds that can activate latent HIV-1. It provides an isolated, latently infected T cell line. Upon treatment with compounds, latent virus can be reactivated and detected by biomarkers. This invention measures both early (egfp) and late (SEAP expression) markers of HIV-1 re-activation via flow cytometry and chemiluminesence respectively. Besides, this technology utilized a latent provirus that was replication-incompetent. The screening can be done under Biosafety Level 2 labs. Therefore, this invention is more accessible and cheaper for facilities to adopt.

Market Applications:

  • Used for high-throughput screening for small molecules or compounds that can reactivate latency HIV-1 virus
  • Compounds identified can be combined with current HIV therapy to increase efficacy.

Advantages:

  • Fast and easy cell-based assay
  • Safe system, which can be done under Biosafety Level 2 guideline
  • Screening can be scaled up to 384-well

Intellectual Property & Development Status:

Patent numbers US 8247167 and US 9017935. Available for licensing and/or research collaboration

Original languageEnglish (US)
StatePublished - Oct 2016
Externally publishedYes

Fingerprint

Anti-HIV Agents
HIV-1
Viruses
High-Throughput Screening Assays
Intellectual Property
Technology
T-Lymphocytes
Proviruses
Licensure
Half-Life
Flow Cytometry
Therapeutics
Biomarkers
HIV
Guidelines
Cell Line
Infection
Research
Population

Cite this

Dougherty, J., Pacchia, A., Peltz, S., Ron, Y., & Micheva-Viteva, S. (2016). A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs.
Dougherty, Joseph (Inventor) ; Pacchia, Annmarie (Inventor) ; Peltz, Stuart (Inventor) ; Ron, Yacov (Inventor) ; Micheva-Viteva, Sofiya (Inventor). / A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs.
@misc{7ab9c2bc1d884bbc8d970c45fd62be06,
title = "A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs",
abstract = "Invention Summary: Background: Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication of virus in patients. The half-life of the latently infected population is quite long. To fully eliminate virus, small molecules that can reach and activate latent viral reservoirs could potentially be utilized to eliminate the latent arm of the infection by the combination with current antiretroviral therapy. Invention: This technology is a cell-based assay for high-throughput screening for novel compounds that can activate latent HIV-1. It provides an isolated, latently infected T cell line. Upon treatment with compounds, latent virus can be reactivated and detected by biomarkers. This invention measures both early (egfp) and late (SEAP expression) markers of HIV-1 re-activation via flow cytometry and chemiluminesence respectively. Besides, this technology utilized a latent provirus that was replication-incompetent. The screening can be done under Biosafety Level 2 labs. Therefore, this invention is more accessible and cheaper for facilities to adopt. Market Applications: Used for high-throughput screening for small molecules or compounds that can reactivate latency HIV-1 virus Compounds identified can be combined with current HIV therapy to increase efficacy. Advantages: Fast and easy cell-based assay Safe system, which can be done under Biosafety Level 2 guideline Screening can be scaled up to 384-well Intellectual Property & Development Status: Patent numbers US 8247167 and US 9017935. Available for licensing and/or research collaboration",
author = "Joseph Dougherty and Annmarie Pacchia and Stuart Peltz and Yacov Ron and Sofiya Micheva-Viteva",
year = "2016",
month = "10",
language = "English (US)",
type = "Patent",

}

Dougherty, J, Pacchia, A, Peltz, S, Ron, Y & Micheva-Viteva, S 2016, A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs.

A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs. / Dougherty, Joseph (Inventor); Pacchia, Annmarie (Inventor); Peltz, Stuart (Inventor); Ron, Yacov (Inventor); Micheva-Viteva, Sofiya (Inventor).

Research output: Innovation

TY - PAT

T1 - A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs

AU - Dougherty, Joseph

AU - Pacchia, Annmarie

AU - Peltz, Stuart

AU - Ron, Yacov

AU - Micheva-Viteva, Sofiya

PY - 2016/10

Y1 - 2016/10

N2 - Invention Summary: Background: Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication of virus in patients. The half-life of the latently infected population is quite long. To fully eliminate virus, small molecules that can reach and activate latent viral reservoirs could potentially be utilized to eliminate the latent arm of the infection by the combination with current antiretroviral therapy. Invention: This technology is a cell-based assay for high-throughput screening for novel compounds that can activate latent HIV-1. It provides an isolated, latently infected T cell line. Upon treatment with compounds, latent virus can be reactivated and detected by biomarkers. This invention measures both early (egfp) and late (SEAP expression) markers of HIV-1 re-activation via flow cytometry and chemiluminesence respectively. Besides, this technology utilized a latent provirus that was replication-incompetent. The screening can be done under Biosafety Level 2 labs. Therefore, this invention is more accessible and cheaper for facilities to adopt. Market Applications: Used for high-throughput screening for small molecules or compounds that can reactivate latency HIV-1 virus Compounds identified can be combined with current HIV therapy to increase efficacy. Advantages: Fast and easy cell-based assay Safe system, which can be done under Biosafety Level 2 guideline Screening can be scaled up to 384-well Intellectual Property & Development Status: Patent numbers US 8247167 and US 9017935. Available for licensing and/or research collaboration

AB - Invention Summary: Background: Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication of virus in patients. The half-life of the latently infected population is quite long. To fully eliminate virus, small molecules that can reach and activate latent viral reservoirs could potentially be utilized to eliminate the latent arm of the infection by the combination with current antiretroviral therapy. Invention: This technology is a cell-based assay for high-throughput screening for novel compounds that can activate latent HIV-1. It provides an isolated, latently infected T cell line. Upon treatment with compounds, latent virus can be reactivated and detected by biomarkers. This invention measures both early (egfp) and late (SEAP expression) markers of HIV-1 re-activation via flow cytometry and chemiluminesence respectively. Besides, this technology utilized a latent provirus that was replication-incompetent. The screening can be done under Biosafety Level 2 labs. Therefore, this invention is more accessible and cheaper for facilities to adopt. Market Applications: Used for high-throughput screening for small molecules or compounds that can reactivate latency HIV-1 virus Compounds identified can be combined with current HIV therapy to increase efficacy. Advantages: Fast and easy cell-based assay Safe system, which can be done under Biosafety Level 2 guideline Screening can be scaled up to 384-well Intellectual Property & Development Status: Patent numbers US 8247167 and US 9017935. Available for licensing and/or research collaboration

UR - http://rutgers.technologypublisher.com/tech?title=A_Virus%2fCell_Based_Assay_for_Discovery_of_Anti-HIV_Drugs

M3 - Innovation

ER -

Dougherty J, Pacchia A, Peltz S, Ron Y, Micheva-Viteva S, inventors. A Virus/Cell Based Assay for Discovery of Anti-HIV Drugs. 2016 Oct.